Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 8/20 | 0.50 |
| ▸ | FLT4 | P35916 | 8/20 | 0.50 |
| ▸ | KDR | P35968 | 8/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.45 |
| ▸ | VCP | P55072 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22925665 | 1.00 | FLT1 (0.50) | FLT1FLT4KDRALOX5TRPV1 | |
| SCHEMBL29621056 | 0.93 | FLT1 (0.52) | FLT1FLT4KDRALOX5TRPV1 | |
| SCHEMBL22925664 | 0.93 | FLT1 (0.52) | FLT1FLT4KDRALOX5TRPV1 | |
| SCHEMBL22925577 | 0.90 | ALOX5 (0.53) | FLT1FLT4KDRALOX5TRPV1 | |
| SCHEMBL22925569 | 0.84 | TRPV1 (0.47) | FLT1FLT4KDRALOX5TRPV1 | |
| SCHEMBL22925600 | 0.82 | TRPV1 (0.45) | FLT1FLT4KDRALOX5TRPV1 | |
| SCHEMBL29620893 | 0.81 | IMPDH2 (0.43) | FLT1FLT4KDRALOX5TRPV1 | |
| SCHEMBL22925667 | 0.81 | IMPDH2 (0.43) | FLT1FLT4KDRALOX5TRPV1 | |
| SCHEMBL24637048 | 0.81 | ALOX5 (0.55) | FLT1FLT4KDRALOX5TRPV1 | |
| SCHEMBL29620925 | 0.80 | TRPV1 (0.48) | FLT1FLT4KDRALOX5TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001870-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2026-01-01 | — | — | US | disclosed |
| US-12448371-B2 | Inhibitor compounds | Cincera Therapeutics Pty Ltd (AU) | 2025-10-21 | — | — | US | disclosed |
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | FLT1 2567/4885FLT4 3701/4885KDR 3951/4885 |
| US-20260001870-A1 | INHIBITOR COMPOUNDS | CES1, NCEH1, NR1H2 | FLT1 2182/4885FLT4 3558/4885KDR 3311/4885 |
| US-12448371-B2 | Inhibitor compounds | SERPINB1, MMP1, SSB | FLT1 2567/4885FLT4 3701/4885KDR 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.